SIREN : 453107625
ANTIBOPTIC is a French company founded 22 years ago, specialized in the sector Commerces de détail d'optique. Based in AMILLY (45200), this company of category PME shows in 2023 a net income positive of 199 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2022 | 2020 | 2017 |
|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C |
| Net income | 199 359 € | 157 248 € | 221 260 € | 191 477 € |
| EBITDA | N/C | N/C | N/C | N/C |
| Net margin | N/C | N/C | N/C | N/C |
In 2023, ANTIBOPTIC generates positive net income of 199 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2023: 191 k€ -> 199 k€.
199 359 €
The debt ratio (= Financial debt / Equity x 100) stands at 65%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 46%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
65.457%
45.768%
30.7%
In 2023, the debt ratio of ANTIBOPTIC (65.46) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2023, the financial autonomy of ANTIBOPTIC (45.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
The liquidity ratio (= Current assets / Current liabilities) stands at 319.40. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
319.403
In 2023, the liquidity ratio of ANTIBOPTIC (319.40) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Based on 100 transactions of similar company sales in 2023, the value of ANTIBOPTIC is estimated at 832 243 € (range 399 869€ - 1 891 451€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 100 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ANTIBOPTIC with other companies in the same sector:
Voir toutes les statistiques du secteur Commerces de détail d'optique
The revenue of ANTIBOPTIC is not publicly disclosed (confidential accounts filed with INPI).
Yes, ANTIBOPTIC generated a net profit of 199 k€ in 2023.
The headquarters of ANTIBOPTIC is located in AMILLY (45200), in the department Loiret.
The tax return of ANTIBOPTIC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ANTIBOPTIC operates in the sector Commerces de détail d'optique (NAF code 47.78A). See the 'Sector positioning' section above to compare the company with its competitors.